ES2256415T3 - Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a. - Google Patents

Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a.

Info

Publication number: ES2256415T3
Authority: ES; Spain
Prior art keywords: pde10a; agent; baselineskip; polypeptide; cgmp
Prior art date: 2001-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES02254973T

Other languages

English (en)

Spanish (es)

Inventor

Larry Carlton James

Lorraine Ann Lebel

Frank Samuel Menniti

Christine Ann Strick

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2002-07-16

Publication date

2006-07-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23196146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2256415(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-07-16 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2006-07-16 Application granted granted Critical

2006-07-16 Publication of ES2256415T3 publication Critical patent/ES2256415T3/es

2022-07-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000012360 testing method Methods 0.000 title claims abstract description 22
101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 claims abstract description 129
102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 claims abstract description 123
210000004027 cell Anatomy 0.000 claims abstract description 93
238000000034 method Methods 0.000 claims abstract description 82
239000003795 chemical substances by application Substances 0.000 claims abstract description 64
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims abstract description 50
230000000694 effects Effects 0.000 claims abstract description 45
210000002569 neuron Anatomy 0.000 claims abstract description 37
229930008281 A03AD01 - Papaverine Natural products 0.000 claims abstract description 25
229960001789 papaverine Drugs 0.000 claims abstract description 25
210000001577 neostriatum Anatomy 0.000 claims abstract description 22
229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 claims abstract description 19
102000030621 adenylate cyclase Human genes 0.000 claims abstract description 7
108060000200 adenylate cyclase Proteins 0.000 claims abstract description 7
230000003834 intracellular effect Effects 0.000 claims abstract description 3
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims abstract 9
108090000765 processed proteins & peptides Proteins 0.000 claims description 87
102000004196 processed proteins & peptides Human genes 0.000 claims description 80
229920001184 polypeptide Polymers 0.000 claims description 77
102000040430 polynucleotide Human genes 0.000 claims description 46
108091033319 polynucleotide Proteins 0.000 claims description 46
239000002157 polynucleotide Substances 0.000 claims description 46
150000007523 nucleic acids Chemical group 0.000 claims description 36
239000013598 vector Substances 0.000 claims description 26
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 22
108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
238000000338 in vitro Methods 0.000 claims description 16
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 11
125000003275 alpha amino acid group Chemical group 0.000 claims description 11
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 11
108091026890 Coding region Proteins 0.000 claims description 10
108010078321 Guanylate Cyclase Proteins 0.000 claims description 7
102000014469 Guanylate cyclase Human genes 0.000 claims description 7
XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 3
229940083618 sodium nitroprusside Drugs 0.000 claims description 3
238000000099 in vitro assay Methods 0.000 claims description 2
101710095468 Cyclase Proteins 0.000 abstract description 2
230000003213 activating effect Effects 0.000 abstract description 2
RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 abstract description 2
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 46
108090000623 proteins and genes Proteins 0.000 description 46
101100028927 Rattus norvegicus Pde10a gene Proteins 0.000 description 40
108020004414 DNA Proteins 0.000 description 36
230000014509 gene expression Effects 0.000 description 36
241000700159 Rattus Species 0.000 description 29
238000009396 hybridization Methods 0.000 description 28
102000004169 proteins and genes Human genes 0.000 description 26
210000004556 brain Anatomy 0.000 description 25
238000003752 polymerase chain reaction Methods 0.000 description 25
239000012634 fragment Substances 0.000 description 23
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 21
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 20
125000003729 nucleotide group Chemical group 0.000 description 20
238000003556 assay Methods 0.000 description 19
239000002773 nucleotide Substances 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
241000700157 Rattus norvegicus Species 0.000 description 16
102000039446 nucleic acids Human genes 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
239000003112 inhibitor Substances 0.000 description 14
108020004999 messenger RNA Proteins 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
241000282414 Homo sapiens Species 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 13
125000004122 cyclic group Chemical group 0.000 description 13
239000013604 expression vector Substances 0.000 description 13
239000000523 sample Substances 0.000 description 13
239000002299 complementary DNA Substances 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
238000002869 basic local alignment search tool Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000003999 initiator Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
239000000758 substrate Substances 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
239000006166 lysate Substances 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
230000014616 translation Effects 0.000 description 8
238000013519 translation Methods 0.000 description 8
238000010367 cloning Methods 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
239000003550 marker Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
108010083644 Ribonucleases Proteins 0.000 description 6
102000006382 Ribonucleases Human genes 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000000692 anti-sense effect Effects 0.000 description 6
230000027455 binding Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000004925 denaturation Methods 0.000 description 6
230000036425 denaturation Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
210000001009 nucleus accumben Anatomy 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
238000005406 washing Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000005755 formation reaction Methods 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
101710176177 Protein A56 Proteins 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
230000001351 cycling effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
239000000185 hemagglutinin Substances 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000001010 olfactory tubercle Anatomy 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
238000001262 western blot Methods 0.000 description 4
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
102000005720 Glutathione transferase Human genes 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
102100036407 Thioredoxin Human genes 0.000 description 3
241000723873 Tobacco mosaic virus Species 0.000 description 3
230000003281 allosteric effect Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
235000013339 cereals Nutrition 0.000 description 3
238000007385 chemical modification Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000003365 immunocytochemistry Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000011049 pearl Substances 0.000 description 3
230000001323 posttranslational effect Effects 0.000 description 3
210000002637 putamen Anatomy 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 3
229950005741 rolipram Drugs 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
108060008226 thioredoxin Proteins 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 3
229950005371 zaprinast Drugs 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
108091060211 Expressed sequence tag Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101100028926 Mus musculus Pde10a gene Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 2
239000003391 RNA probe Substances 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000006473 carboxylation reaction Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
-1 cofactors Substances 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
102000054918 human PDE10A Human genes 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
239000007858 starting material Substances 0.000 description 2
210000001977 striatum neuron Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
BALXSYQWXWVVJJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphoric acid Chemical compound OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 BALXSYQWXWVVJJ-UHFFFAOYSA-N 0.000 description 1
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 description 1
241000345998 Calamus manan Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000173351 Camvirus Species 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
244000163122 Curcuma domestica Species 0.000 description 1
235000003392 Curcuma domestica Nutrition 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 description 1
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
101001072031 Drosophila melanogaster Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11 Proteins 0.000 description 1
101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
102000012074 GAF domains Human genes 0.000 description 1
108050002598 GAF domains Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
102100024228 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001117261 Homo sapiens High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Proteins 0.000 description 1
101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 1
101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108700015679 Nested Genes Proteins 0.000 description 1
108091005461 Nucleic proteins Chemical group 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108010038807 Oligopeptides Chemical group 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
101150098694 PDE5A gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
108010001441 Phosphopeptides Proteins 0.000 description 1
101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000220010 Rhode Species 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
108010046983 Ribonuclease T1 Proteins 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
235000010208 anthocyanin Nutrition 0.000 description 1
239000004410 anthocyanin Substances 0.000 description 1
229930002877 anthocyanin Natural products 0.000 description 1
150000004636 anthocyanins Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 1
102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
102100037093 cGMP-inhibited 3',5'-cyclic phosphodiesterase A Human genes 0.000 description 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000019771 cognition Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000005226 corpus cavernosum Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
235000003373 curcuma longa Nutrition 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical compound CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 description 1
210000001029 dorsal striatum Anatomy 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000004101 entopeduncular nucleus Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
210000001308 heart ventricle Anatomy 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000002425 internal capsule Anatomy 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
230000031852 maintenance of location in cell Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
229960002460 nitroprusside Drugs 0.000 description 1
230000037360 nucleotide metabolism Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000002360 prefrontal effect Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000026447 protein localization Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
235000012950 rattan cane Nutrition 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000002805 secondary assay Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000005250 spinal neuron Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
238000013334 tissue model Methods 0.000 description 1
150000004992 toluidines Chemical class 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
235000013976 turmeric Nutrition 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
210000001030 ventral striatum Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ES02254973T 2001-07-31 2002-07-16 Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a. Expired - Lifetime ES2256415T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30897801P	2001-07-31	2001-07-31
US308978P		2001-07-31

Publications (1)

Publication Number	Publication Date
ES2256415T3 true ES2256415T3 (es)	2006-07-16

Family

ID=23196146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES02254973T Expired - Lifetime ES2256415T3 (es)	2001-07-31	2002-07-16	Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a.

Country Status (7)

Country	Link
US (2)	US20030096323A1 (fr)
EP (1)	EP1281771B1 (fr)
JP (3)	JP2003135079A (fr)
AT (1)	ATE321147T1 (fr)
CA (1)	CA2391117A1 (fr)
DE (1)	DE60210014T2 (fr)
ES (1)	ES2256415T3 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030032579A1 (en) *	2001-04-20	2003-02-13	Pfizer Inc.	Therapeutic use of selective PDE10 inhibitors
US8338420B1 (en)	2002-12-04	2012-12-25	Mitsubishi Tanabe Pharma Corporation	Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
EP1608743A2 (fr) *	2003-04-03	2005-12-28	Memory Pharmaceutical Corporation	Isoformes de la phosphodiesterase 10a7 et leurs methodes d'utilisation
EP1651251A4 (fr) *	2003-07-31	2008-06-18	Bayer Pharmaceuticals Corp	Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
US9085798B2 (en) *	2009-04-30	2015-07-21	Prognosys Biosciences, Inc.	Nucleic acid constructs and methods of use
US20190300945A1 (en)	2010-04-05	2019-10-03	Prognosys Biosciences, Inc.	Spatially Encoded Biological Assays
US10787701B2 (en)	2010-04-05	2020-09-29	Prognosys Biosciences, Inc.	Spatially encoded biological assays
WO2011127099A1 (fr)	2010-04-05	2011-10-13	Prognosys Biosciences, Inc.	Tests biologiques à codage spatial
EP2694709B1 (fr)	2011-04-08	2016-09-14	Prognosys Biosciences, Inc.	Constructions peptidiques et systèmes d'essai
GB201106254D0 (en)	2011-04-13	2011-05-25	Frisen Jonas	Method and product
EP4592400A3 (fr)	2012-10-17	2025-10-29	10x Genomics Sweden AB	Procédés et produits pour optimiser la detection localisée ou spatiale de l'expression génique dans un échantillon de tissu
EP3736573A1 (fr)	2013-03-15	2020-11-11	Prognosys Biosciences, Inc.	Procédés de détection de liaison peptide/mhc/tcr
CA2916662C (fr)	2013-06-25	2022-03-08	Prognosys Biosciences, Inc.	Procedes et systemes pour determiner des motifs spatiales de cibles biologiques dans un echantillon
US10288608B2 (en)	2013-11-08	2019-05-14	Prognosys Biosciences, Inc.	Polynucleotide conjugates and methods for analyte detection
EP3901282B1 (fr)	2015-04-10	2023-06-28	Spatial Transcriptomics AB	Analyse de plusieurs acides nucléiques spatialement différenciés de spécimens biologiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0967284A1 (fr) *	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiestérases

2002
- 2002-07-16 AT AT02254973T patent/ATE321147T1/de not_active IP Right Cessation
- 2002-07-16 DE DE60210014T patent/DE60210014T2/de not_active Expired - Fee Related
- 2002-07-16 ES ES02254973T patent/ES2256415T3/es not_active Expired - Lifetime
- 2002-07-16 EP EP02254973A patent/EP1281771B1/fr not_active Expired - Lifetime
- 2002-07-24 US US10/202,107 patent/US20030096323A1/en not_active Abandoned
- 2002-07-26 JP JP2002217718A patent/JP2003135079A/ja active Pending
- 2002-07-29 CA CA002391117A patent/CA2391117A1/fr not_active Abandoned
2004
- 2004-07-08 US US10/887,276 patent/US20050026236A1/en not_active Abandoned
2005
- 2005-07-27 JP JP2005217438A patent/JP2005328850A/ja active Pending
- 2005-07-27 JP JP2005217435A patent/JP2006006337A/ja not_active Ceased

Also Published As

Publication number	Publication date
JP2006006337A (ja)	2006-01-12
US20030096323A1 (en)	2003-05-22
EP1281771A3 (fr)	2004-01-02
EP1281771B1 (fr)	2006-03-22
DE60210014T2 (de)	2006-09-21
EP1281771A2 (fr)	2003-02-05
DE60210014D1 (de)	2006-05-11
JP2003135079A (ja)	2003-05-13
JP2005328850A (ja)	2005-12-02
ATE321147T1 (de)	2006-04-15
US20050026236A1 (en)	2005-02-03
CA2391117A1 (fr)	2003-01-31

Publication	Publication Date	Title
ES2256415T3 (es)	2006-07-16	Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a.
Day et al.	2005	Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
CN101542288A (zh)	2009-09-23	鉴别trpv2的调节剂的组合物和方法
MacPherson et al.	2004	Analysis of Drosophila cGMP-dependent protein kinases and assessment of their in vivo roles by targeted expression in a renal transporting epithelium
Wimberg et al.	2018	Control of the nucleotide cycle in photoreceptor cell extracts by retinal degeneration protein 3
JP2001505779A (ja)	2001-05-08	Ｐｙｋ２関連産物および方法
JP2003526608A (ja)	2003-09-09	再分布及び／又は標的化での干渉によって得られる特異的治療の介入
US6544768B1 (en)	2003-04-08	Mammalian soluble adenylyl cyclase
US7060810B2 (en)	2006-06-13	Regulation of human eosinophil serine protease 1-like enzyme
Ureña et al.	2005	Expression, synaptic localization, and developmental regulation of Ack1/Pyk1, a cytoplasmic tyrosine kinase highly expressed in the developing and adult brain
Sekito et al.	2005	Stimulation of transforming activity of DJ-1 by Abstrakt, a DJ-1-binding protein
US20030073097A1 (en)	2003-04-17	TRAF6-regulated IKK activators (TRIKA1 and TRIKA2) and their use as anti-inflammatory targets
Nigg et al.	2007	Regulation of p34cdc2 protein kinase activity by phosphorylation and cyclin binding
CA2525915C (fr)	2007-12-18	Sequences et epreuve ayant trait a l'activite cellulaire de la phosphodiesterase 10a
Bai et al.	1998	Cultured sympathetic neurons express functional interleukin-1 receptors
Strick et al.	2006	PDE10A: a striatum-enriched, dual-substrate phosphodiesterase
ES2347247T3 (es)	2010-10-27	Regulacion de una quinasa, 'quinasa regulada en epoc' (quinasa rc).
ES2291362T3 (es)	2008-03-01	Procedimientos de cribado para identificar proteinas g y otros compuestos que modulan la actividad de la fosfodiesterasa (pde).
US7205135B2 (en)	2007-04-17	Regulation of human adenylate cyclase
ES2288556T3 (es)	2008-01-16	Procedimiento de screening empleando bnpi y dnpi.
JP2006510343A (ja)	2006-03-30	ヒトｔｒｐチャネルの調節
ES2276964T3 (es)	2007-07-01	Procedimiento de screening que utiliza bnpi para diferentes indicaciones.
WO2002024878A2 (fr)	2002-03-28	Regulation d'enzyme du type proteine ubiquitine ligase (e3) humaine
US20050130138A1 (en)	2005-06-16	Immune-related proteins and the regulation of the same
US20040029247A1 (en)	2004-02-12	Regulation of human adenylate cyclase, type iv